Tumour Models London
- Start Date:
- Tuesday, 5 December, 2017
- End Date:
- Thursday, 7 December, 2017 5:00pm
- Health & Nutrition
Tumour Models London returns in its 6th year and takes a reinvigorated approach towards closing the translational gap between predictable preclinical validation and successful clinical development. Learn how industry leaders are harnessing next generation in vitro and in vivo techniques to better predict efficacy and toxicity into the clinic; and fast track suitable drug candidates by effectively and accurately mimicking the tumour microenvironment.
Discover innovative ways in which the industry is developing humanised mice and generating preclinical data, to advance immunotherapies across the translational gap. Translate learnings not only from preclinical data packages of new candidates, but by retrospectively analysing clinical trial data to create robust and informative preclinical models that improve translational decision making. As 2017 comes to a close, join the most trusted and assured meeting dedicated to help you predict the clinical outcome of your drug candidates more accurately through the effective application of well characterised and predictable preclinical models.
Brochure: https://go.evvnt.com/143729-0 Speakers: Frank Schnieders, CEO, Provecs Medical | Michael Rugaard Jensen, Head of Drug Discovery Pharmacology, Novartis | Dr. Vinagolu Rajasekhar, Senior Research Scientist, Memorial Sloan Kettering Cancer Center | Daniel Hynes, Preclinical Manager, E-therapeutics |
No. 1 Westferry Circus,
Conference organized by Hanson Wade Ltd